Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2011 ) > List of Articles


Histopathological Assessment of Liver Biopsy Specimen in the Context of HBV DNA and HBeAg in Patients with Chronic Hepatitis B

Naznin Nahar, AJE Nahar Rahman, Saequa Habib

Citation Information : Nahar N, Nahar Rahman A, Habib S. Histopathological Assessment of Liver Biopsy Specimen in the Context of HBV DNA and HBeAg in Patients with Chronic Hepatitis B. Euroasian J Hepatogastroenterol 2011; 1 (2):83-88.

DOI: 10.5005/jp-journals-10018-1018

License: CC BY-NC 4.0

Published Online: 01-01-2011

Copyright Statement:  Copyright © 2011; The Author(s).


Background: There is lack of consensus if hepatitis B virus (HBV) DNA can be regarded as a surrogate marker of liver damages in patients with chronic hepatitis B (CHB). Methods: A total of 77 patients with CHB were enrolled in this study. The sera of the patients were tested for HBV DNA and hepatitis B e antigen (HBeAg). The extent of hepatitis and hepatic fibrosis was assessed by liver biopsy. Results: Out of total of 77 patients with CHB, 29 were HBeAg-positive and 48 were HBeAg-negative. Twenty-seven of 29 HBeAg-positive patients and eight of 48 HBeAg-negative patients had high levels of HBV DNA (HBV DNA>105 copies/ml). The extent of hepatitis was minimal or mild in most HBeAg-positive CHB patients (27 of 29) irrespective of the levels of HBV DNA in the sera. Moderate levels of hepatitis were seen in two HBeAg-positive patients and five HBeAg-negative patients. Moderate levels of hepatic fibrosis were seen in four of eight HBeAg-negative patients with high HBV DNA. Conclusion: This study shows that HBV DNA and HBeAg do not reflect the extent of hepatitis or hepatic fibrosis in CHB patients of Bangladesh. Combination of different HBV-related markers with liver biopsy is required for proper diagnosis and management of CHB in Bangladesh.

PDF Share
  1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. New Eng J Med 2004;350:1118-29
  2. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52
  3. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
  4. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
  5. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Curr Hepat Rep 2007;6:9-16
  6. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-89
  7. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007;46: 1057-70
  8. Is there a meaningful serum hepatitis B virus DNA cut-off level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451-59
  9. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134:1376-84
  10. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009;136:1272-80
  11. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: Implications for therapy. Am J Gastroenterol 2009;104:906-11
  12. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009;104:1693-99
  13. Correlation between serum transaminase level and HAI score in chronic hepatitis B. Ind J Gastroenterol 2005;24:124
  14. al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;4:431-35
  15. Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 2010;202:1309-18
  16. On-treatment monitoring of HBV DNA levels: Predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3(Suppl 1):16-23
  17. AASLD Guidelines Chronic hepatitis B; Update 2009; Hepatology 2009;50:1-36
  18. EASL clinical practice guidelines. Management of chronic hepatitis B. J Hepatol 2009;50:227-42
  19. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;22:262-83
  20. Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. Journal of Medical Virology 2010;82:1350-54
  21. Treatment of hepatitis B virus-infected patients: Utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10: 1605-14
  22. Future aspects of therapy for hepatitis B virus infection: Value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol (in press)
  23. Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia. J Hepatol 2009;51:403-07.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.